Sun Tao, Liu Xinfeng, Li Ming
aDepartment of Neurology, Jinling Hospital, Nanjing University School of Medicine, Nanjing, China bDepartment of Psychology, University of Nebraska-Lincoln, Lincoln, Nebraska, USA.
Behav Pharmacol. 2014 Aug;25(4):277-86. doi: 10.1097/FBP.0000000000000047.
Previous studies have reported that context can powerfully modulate the inhibitory effect of an antipsychotic drug on phencyclidine (PCP)-induced hyperlocomotion (a behavioral test used to evaluate putative antipsychotic drugs). The present study investigated the experimental conditions under which environmental stimuli exert their influence through associative conditioning processes. Experiment 1 examined the extent to which previous antipsychotic treatment in the home cages affected a drug's ability to inhibit PCP-induced hyperlocomotion in novel motor activity test apparatus. Five days of repeated haloperidol (0.05 mg/kg, subcutaneously) and olanzapine (2.0 mg/kg, subcutaneously) treatment in the home cages still potentiated their inhibition of PCP-induced hyperlocomotion (i.e. sensitization) assessed in a new environment, whereas the clozapine (10.0 mg/kg, subcutaneously) treatment enhanced the development of clozapine tolerance, indicating a lack of environmental modulation of antipsychotic efficacy. Experiment 2 assessed the impact of different numbers of antipsychotic administrations (e.g. 4, 2 or 0), in either the home environment or test environment, on a drug's ability to inhibit PCP-induced hyperlocomotion. Repeated administration of clozapine (5.0 mg/kg, subcutaneously) or olanzapine (1.0 mg/kg, subcutaneously) for 4 consecutive days, irrespective of where these treatments occurred, led to a similar level of inhibition of PCP-induced hyperlocomotion. However, 4-day haloperidol (0.03 mg/kg, subcutaneously) treatment in the test apparatus led to significantly higher inhibition than a 4-day home-cage treatment. Thus, more exposures to the test environment under the influence of haloperidol (but not clozapine or olanzapine) caused a stronger inhibition than fewer exposures, indicating a strong environmental modulation. Collectively, these findings suggest that previous antipsychotic treatment in one environment could alter later antipsychotic-like response assessed in a different environment under certain test conditions. Therefore, whether the circumstances surrounding antipsychotic drug administration have a powerful effect on the expression of antipsychotic-like efficacy is dependent on specific experimental and drug treatment factors.
先前的研究报告称,环境能够有力地调节抗精神病药物对苯环己哌啶(PCP)诱导的运动亢进(一种用于评估假定抗精神病药物的行为测试)的抑制作用。本研究调查了环境刺激通过联想性条件作用过程发挥影响的实验条件。实验1考察了在饲养笼中预先进行抗精神病药物治疗对药物在新型运动活动测试装置中抑制PCP诱导的运动亢进能力的影响程度。在饲养笼中连续5天重复给予氟哌啶醇(0.05毫克/千克,皮下注射)和奥氮平(2.0毫克/千克,皮下注射),仍能增强它们对在新环境中评估的PCP诱导的运动亢进的抑制作用(即致敏作用),而氯氮平(10.0毫克/千克,皮下注射)治疗则增强了氯氮平耐受性的发展,表明抗精神病药物疗效缺乏环境调节作用。实验2评估了在饲养环境或测试环境中给予不同次数的抗精神病药物(如4次、2次或0次)对药物抑制PCP诱导的运动亢进能力的影响。连续4天重复给予氯氮平(5.0毫克/千克,皮下注射)或奥氮平(1.0毫克/千克,皮下注射),无论这些治疗在何处进行,都导致对PCP诱导的运动亢进的抑制水平相似。然而,在测试装置中进行4天的氟哌啶醇(0.03毫克/千克,皮下注射)治疗比在饲养笼中进行4天的治疗导致的抑制作用明显更高。因此,在氟哌啶醇(但不是氯氮平或奥氮平)影响下更多次暴露于测试环境比更少次暴露导致更强的抑制作用,表明存在强大的环境调节作用。总体而言,这些发现表明,在一种环境中预先进行抗精神病药物治疗可能会改变在特定测试条件下在不同环境中评估的后续类抗精神病反应。因此,抗精神病药物给药时的环境情况是否对类抗精神病疗效的表达有强大影响取决于特定的实验和药物治疗因素。